US President Donald Trump has announced steep tariffs on imported generic medicines. The move is designed to encourage pharmaceutical manufacturers to relocate production to the United States. Trump said generic medicines would remain tariff-free for two years from 1 August 2026. A 100% tariff would then apply for one year from August 2028. This would increase to 200% from August…
Tag: Biosimilars
-
FDA Biosimilar Development Guidance Targets Treatment Costs
\n\nBiologic medicines are made from living cells and are among the most expensive therapies available. While they account for only 5% of all prescriptions, they are responsible for a staggering 51% of total drug spending in the United States. To address this imbalance, the FDA is prioritising the expansion of the biosimilar market.\n\n\n\nThe new FDA biosimilar development guidance focuses on…